Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at...
- UCLH initiates new trial for Alzheimer’s treatment in UK
- Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi
- Hereditary Alzheimer’s: could rare genes hold the key to a cure?
- NHS wins landmark ruling against pharma companies over AMD drug
- Blood Cancer Awareness Month: revolutionary treatments in the pipeline
Trial design should give Dermira’s AD drug a better shot at Phase IIb success
Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.
Roche’s Hemlibra: a (Bi)-specific shift in the hemophilia A market
The hemophilia drug market is currently undergoing major changes due to advances in recombinant protein engineering, as well as the introduction of gene therapy and novel strategies to target the coagulation cascade.
Immugenyx and Janssen to develop SLE model for drug development
Immugenyx has signed a collaboration agreement with Janssen Research & Development to develop an in-vivo platform that will aid in treating systemic lupus erythematosus (SLE).
Roche makes a cautious investment in Ionis’ dAMD drug
Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx, an antisense pipeline drug using Ionis’ advanced Ligand Conjugated Antisense (LICA) technology, which reduces the production of Factor B, a key protein in the complement innate immune system in a broad range of diseases.
ESMO 2018: previewing high-impact, late-breaking abstracts
The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical research abstracts. The best studies at the congress, those considered cutting-edge or practice-changing, will be presented during the three plenary sessions, called Presidential Symposia at ESMO.
AbbVie/J&J’s Imbruvica expected to post encouraging PFS rates in CLL
A 7.5-year follow-up of AbbVie and Johnson & Johnson’s Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) found that the seven-year progression-free survival (PFS) rate is more than 90% for low-risk patients and 30%–40% for high-risk patients.
Almirall brings new drug to stagnant US acne market
On October 2, the FDA approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older. Seysara was originally developed by Paratek Pharmaceuticals.
AbbVie’s risankizumab has uptake caveats despite anticipated approvals
AbbVie’s risankizumab for moderate-to-severe plaque psoriasis will likely face market hurdles despite highly expected regulatory approvals.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.